### 2026-08-04 16:14 UTC 自动交叉验证
- P&L: +0.7%
- 4大师速览: BULLISH
BUFFETT: HOLD — durable moat across diversified healthcare verticals
MUNGER: Mistake if regulatory shocks collapse medical device pricing power
DUAN: Yes, essential structural growth in aging populations
LI_LU: Low risk of permanent loss, steady long-term compounder
OVERALL: BULLISH
- Serenity速览: UNKNOWN

- **升级触发**: 从未做过深度复核
- **付费深度判断** ($0.0793): **论文是否成立**：ABT 从未存过论文文件，这次触发本质上是"文档缺失"而非"基本面恶化"——和之前 TEL 那次误报是同一模式（[[project_crossvalidate_missing_thesis_false_positive]]），不代表持仓真出了问题。

**本地四大师判断**：整体站得住。ABT 是诊断（Alinity）+ 医疗器械（FreeStyle Libre CGN 增长引擎）+ 营养+仿制药的多元防御型资产，老龄化驱动的结构性需求和稳健现金流支撑巴菲特/段永平/李录的判断；芒格提的"监管冲击打掉器械定价权"是假设性风险，目前没有具体催化剂证实正在发生，属于合理的风险提示而非红旗。Serenity 速览为空是符合预期的——ABT 不在半导体/AI供应链卡点框架的覆盖范围内，这个框架本来就不该对它有意见。

**建议：HOLD**。卫星仓、无杠杆压力、无实际恶化证据，不需要 TRIM/EXIT。下一步用 thesis-tracker 补一份 ABT 论文存档，避免下次交叉验证再对着"没有论文文件"这个技术性缺口误报升级。


### 2026-08-04 20:13 UTC 自动交叉验证
- P&L: +0.3%
- 4大师速览: BULLISH
BUFFETT: HOLD — wide moat via CGM leadership and diversified healthcare streams.
MUNGER: Mistake if glucose monitoring is disrupted by leapfrog technology.
DUAN: Yes, essential healthcare utility with enduring demand.
LI_LU: Low risk of permanent loss, consistent long-term compounder.
OVERALL: BULLISH
- Serenity速览: UNKNOWN



### 2026-08-05 00:19 UTC 自动交叉验证
- P&L: +0.3%
- 4大师速览: BULLISH
BUFFETT: HOLD — Wide moat via diversified healthcare platforms and strong pricing power.
MUNGER: Mistake if FreeStyle Libre's market dominance is disrupted by superior tech.
DUAN(段永平): Yes — Essential healthcare business with secular long-term demand.
LI_LU(李录): Low risk of permanent loss; steady compounding via medical innovation.
OVERALL: BULLISH
- Serenity速览: UNKNOWN



### 2026-08-05 04:19 UTC 自动交叉验证
- P&L: +0.5%
- 4大师速览: BULLISH
BUFFETT: HOLD; wide moat in diagnostics and medical devices.
MUNGER: Mistake if CGM market dominance is disrupted or pricing power erodes.
DUAN(段永平): Yes; essential healthcare business with timeless demand.
LI_LU(李录): Strong long-term compounder; low risk of permanent loss.
OVERALL: BULLISH
- Serenity速览: UNKNOWN



### 2026-08-05 08:20 UTC 自动交叉验证
- P&L: +0.5%
- 4大师速览: UNKNOWN

- Serenity速览: UNKNOWN

- **升级触发**: 本地 Ollama 分析失败(两路都返回空)— 无法交叉验证,人工确认模型是否在线
- **付费深度判断** ($0.1939): **判断：论文本质上未变，属于已知的误报模式，建议 HOLD。**

Ollama 目前确认在线（多个 serve 进程 + 已加载模型在跑），"两路返回空"大概率又是冷启动超时导致的假触发，不是真实的模型下线，也不是基本面信号——这个模式在 [[project_ollama_crossvalidate_false_positive]] 里已经反复出现过。ABT 没有存档论文本来就是"文档缺失"而非"论文破裂"，与之前 TEL 的误报同源（[[project_crossvalidate_missing_thesis_false_positive]]）；事实上过去 12 小时里同一持仓已经连续 4 次跑出本地 4 大师 BULLISH（巴菲特/段永平/李录一致看多，芒格提的监管冲击是假设性风险、无实锤催化剂），Serenity 速览为空也完全合理——ABT（诊断+医疗器械+营养）本就不在半导体/AI 供应链卡点框架的覆盖范围内，Serenity 对它没有意见是预期行为而非信号缺失。

卫星仓、无杠杆压力、无实质恶化证据，**建议 HOLD**，不需要 TRIM/EXIT。

下一步建议：用 thesis-tracker 给 ABT 补一份正式论文存档——updates.md 里已经记了好几次"下一步该补"但一直没做，导致同一个技术性缺口反复触发交叉验证升级，浪费人工确认成本。


### 2026-08-05 12:18 UTC 自动交叉验证
- P&L: +0.3%
- 4大师速览: BULLISH
BUFFETT: HOLD — Wide moat via diverse medical device and diagnostic leadership.
MUNGER: Mistake if FreeStyle Libre growth hits a hard ceiling or regulatory wall.
DUAN: Yes, a high-quality business providing essential healthcare for decades.
LI_LU: Low permanent loss risk due to diversification; structural compounding tailwinds.
OVERALL: BULLISH
- Serenity速览: BULLISH
CHOKEPOINT_INTACT: YES
REASON: continued market dominance and expansion of the FreeStyle Libre CGM ecosystem
OVERALL: BULLISH


### 2026-08-05 16:20 UTC 自动交叉验证
- P&L: -0.7%
- 4大师速览: UNKNOWN

- Serenity速览: UNKNOWN

- **升级触发**: 本地 Ollama 分析失败(两路都返回空)— 无法交叉验证,人工确认模型是否在线
- **付费深度判断** ($0.1589): **判断：Ollama 守护进程本身是活的**（多个 `ollama serve` 进程 + 一个正在跑推理的 runner），这次"两路返回空"和此前记录的 gemma4:31b 冷启动超时误报模式一致——是 crossvalidate 脚本的 120s 超时问题，不是模型真的离线，也不是 ABT 出现了新的负面信号。同时"无原始论文"也是缺档案而非论文被推翻（和之前 TEL 的情况类似）。ABT（雅培）是分散型医疗器械/诊断/营养品的稳定复利股，没有已知的负面催化剂或供应链卡点触发，符合你长期持有、低换手的组合定位。

**结论：HOLD**。这次升级是工具层假信号，不构成减仓/清仓理由；建议后续用 thesis-tracker 给 ABT 补建论文档案，并核查/延长 crossvalidate_satellite.py 的超时设置以减少重复误报（属于已知的运维债务，不需要立即处理）。


### 2026-08-05 20:18 UTC 自动交叉验证
- P&L: +0.4%
- 4大师速览: BULLISH
BUFFETT: HOLD — wide moat via CGM market leadership and diversified medical stables.
MUNGER: Mistake if systemic regulatory failures or litigation destroy brand trust.
DUAN: Yes, an essential health-infrastructure business with high barriers.
LI_LU: Low risk of permanent loss; long-term compounder tied to aging demographics.
OVERALL: BULLISH
- Serenity速览: UNKNOWN



### 2026-08-06 00:19 UTC 自动交叉验证
- P&L: +0.5%
- 4大师速览: BULLISH
BUFFETT: HOLD — Wide moat via diversified healthcare platforms and high switching costs.
MUNGER: Mistake if a disruptive technology renders the glucose monitoring dominance obsolete.
DUAN(段永平): Yes — essential healthcare utility with durable competitive advantages.
LI_LU(李录): Low risk of permanent loss; steady compounding through diversified med-tech.
OVERALL: BULLISH
- Serenity速览: UNKNOWN



